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Editorial 
 
 billion years before the advent of man on 
planet  earth,  bacteria  had  made  it  their 
home. When  competing  species  began  to 
colonize the earth, bacteria had to learn to survive. 
They learnt to evade fungi which secreted antibac-
terial substances, and became adept at surviving--
even  flourishing  -  in  inimical  microenvironments. 
They  found  ways  to  coexist,  and  to  parasitize, 
even. Incredibly, they found ways to talk to other 
micro-organisms,  exchanging  through  plasmids, 
sophisticated  tools  to  build  their  armouries.  And 
through  their  astonishing  ability  to  continually 
transform themselves, they learnt to hide. 
Medicine  continues  to  be  baffled  by  mankind’s 
most ancient enemies. Uncertainty and ignorance 
has led to escalating antibiotic use. For instance 
(according to a popularly quoted study) as many as 
40%  of  prescriptions  for  tuberculosis  contain  er-
rors. 
The  CDC  figures  that  over  25  million  pounds  of 
antibiotics each year are used without good rea-
son—and that’s in the USA alone. Only 50% of all 
antibiotics produced are used therapeutically. The 
rest are used prophylactically in animals and poul-
try, to keep livestock healthy.  Such misuse of anti-
biotics  cannot  be  without  consequences.  It  has 
been shown that each day of antibiotic use in the 
last 6 months ups the infection with Pseudomonas 
by 4%. Nowhere has the impact of antibiotic resis-
tance been felt more profoundly than in the Inten-
sive care unit. Multidrug resistant bacteria are now 
regularly  incriminated  in  many  nosocomial  infec-
tions.  More  and  more  of  the  dreaded  extended-
spectrum  beta-lactamase  (ESBL)  enzymes  are 
identified by the day. 
Once resistance appears in a particular milieu, it is 
almost certain to persist. In spite of the clear and 
present  danger,  antibiotic  misuse  continues.  17 
billion dollars each year go into antibiotic produc-
tion each year, but a hundred billion dollars go into 
the treatment of the consequences of ill-conceived 
treatment: drug resistant infections. In desperation 
clinicians  have  again  turned  to  antibiotics  like 
Colistin and Polymyxin—discarded thirty years ago 
for their toxic potential. 
Even  when  the  pathogens  are  identifiable,  deci-
sions  concerning  antimicrobial  therapy  can  be 
complex. Negative cultures present their own spe-
cial problems. In such cases, it could be that an 
infection has been masked by prior antibiotic use, 
that the culture media used are inappropriate, that 
the  ‘holding  time’  has  not  been  long  enough,  or 
even that the organisms are ‘atypical’ and there-
fore innately resistant to the selected therapy. In 
this issue we take a closer look at culture-negative 
surgical site infections. 
Antibiotics are all that mankind has to combat in-
fections. Virtually no new antibiotics are anticipated 
in  the  immediate  future,  at  least  with  respect  to 
gram-negative  bacillary  infections.  Bacteria  have 
developed  and  refined  their  bio-arsenal  over  the 
aeons,  whereas  Medicine  has  had  just  eighty 
years’ experience with antimicrobial therapy. 
Clearly, the lessons have not been learnt. 
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